[go: up one dir, main page]

SG11202104423XA - Methods of preparing cytotoxic benzodiazepine derivatives - Google Patents

Methods of preparing cytotoxic benzodiazepine derivatives

Info

Publication number
SG11202104423XA
SG11202104423XA SG11202104423XA SG11202104423XA SG11202104423XA SG 11202104423X A SG11202104423X A SG 11202104423XA SG 11202104423X A SG11202104423X A SG 11202104423XA SG 11202104423X A SG11202104423X A SG 11202104423XA SG 11202104423X A SG11202104423X A SG 11202104423XA
Authority
SG
Singapore
Prior art keywords
methods
benzodiazepine derivatives
cytotoxic benzodiazepine
preparing cytotoxic
preparing
Prior art date
Application number
SG11202104423XA
Inventor
Michael Reardon
Richard A Silva
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of SG11202104423XA publication Critical patent/SG11202104423XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
SG11202104423XA 2018-11-12 2019-11-11 Methods of preparing cytotoxic benzodiazepine derivatives SG11202104423XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758819P 2018-11-12 2018-11-12
PCT/US2019/060679 WO2020102053A1 (en) 2018-11-12 2019-11-11 Methods of preparing cytotoxic benzodiazepine derivatives

Publications (1)

Publication Number Publication Date
SG11202104423XA true SG11202104423XA (en) 2021-05-28

Family

ID=68808530

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104423XA SG11202104423XA (en) 2018-11-12 2019-11-11 Methods of preparing cytotoxic benzodiazepine derivatives

Country Status (12)

Country Link
US (3) US10913713B2 (en)
EP (2) EP3880656B1 (en)
JP (1) JP2022512936A (en)
KR (1) KR20210099010A (en)
CN (1) CN113166053A (en)
AU (1) AU2019381628A1 (en)
CA (1) CA3119544A1 (en)
IL (2) IL308670A (en)
MA (1) MA54225A (en)
SG (1) SG11202104423XA (en)
TW (1) TWI849000B (en)
WO (1) WO2020102053A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL308670A (en) 2018-11-12 2024-01-01 Immunogen Inc Methods for preparing cytotoxic benzodiazepine derivatives
AU2022325888A1 (en) 2021-08-13 2024-02-22 Immunogen, Inc. Improved methods for preparing cytotoxic benzodiazepine derivatives
KR20250031149A (en) 2022-06-30 2025-03-06 도레이 카부시키가이샤 Pharmaceutical composition for the treatment and/or prevention of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0708818D0 (en) * 2007-05-08 2007-06-13 Portela & Ca Sa Compounds
EP3666289A1 (en) 2011-02-15 2020-06-17 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
JP7203497B2 (en) * 2015-06-29 2023-01-13 イミュノジェン・インコーポレーテッド Anti-CD123 Antibodies, and Conjugates and Derivatives Thereof
MA42250B1 (en) * 2015-06-29 2020-11-30 Immunogen Inc Cysteine-modified antibody conjugates
CN113004288A (en) * 2015-07-21 2021-06-22 伊缪诺金公司 Method for preparing cytotoxic benzodiazepine derivatives
EP4335851A3 (en) * 2015-11-25 2024-06-05 ImmunoGen, Inc. Pharmaceutical formulations and methods of use thereof
CN116554262A (en) * 2017-01-25 2023-08-08 伊缪诺金公司 Process for preparing cytotoxic benzodiazepine derivatives
TWI827575B (en) * 2017-12-28 2024-01-01 美商伊繆諾金公司 Benzodiazepine derivatives
IL308670A (en) 2018-11-12 2024-01-01 Immunogen Inc Methods for preparing cytotoxic benzodiazepine derivatives

Also Published As

Publication number Publication date
EP4365173A3 (en) 2024-07-17
CN113166053A (en) 2021-07-23
EP3880656A1 (en) 2021-09-22
MA54225A (en) 2021-09-22
WO2020102053A1 (en) 2020-05-22
US11591296B2 (en) 2023-02-28
IL283047A (en) 2021-06-30
US20210230114A1 (en) 2021-07-29
WO2020102053A8 (en) 2020-06-18
JP2022512936A (en) 2022-02-07
AU2019381628A1 (en) 2021-05-27
TW202033498A (en) 2020-09-16
IL283047B1 (en) 2023-12-01
TWI849000B (en) 2024-07-21
IL308670A (en) 2024-01-01
EP3880656B1 (en) 2024-03-20
EP4365173A2 (en) 2024-05-08
US20230286914A1 (en) 2023-09-14
KR20210099010A (en) 2021-08-11
US10913713B2 (en) 2021-02-09
IL283047B2 (en) 2024-04-01
US20200172481A1 (en) 2020-06-04
CA3119544A1 (en) 2020-05-22

Similar Documents

Publication Publication Date Title
IL268737A (en) Processes for the preparation of benzodiazepine derivatives
IL286788B1 (en) Methods of preparing cytotoxic benzodiazepine derivatives
IL287405A (en) Methods of preparing cytotoxic benzodiazepine derivatives
IL283045A (en) Methods of preparing cytotoxic benzodiazepine derivatives
IL283047A (en) Methods of preparing cytotoxic benzodiazepine derivatives
IL276483B1 (en) Continuous process for the preparation of trazodone
IL293192A (en) Methods of preparing indolinobenzodiazepine derivatives
HK40089587A (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK40060522A (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK40060523A (en) Methods of preparing cytotoxic benzodiazepine derivatives
HK40088821A (en) Methods of preparing cytotoxic benzodiazepine derivatives